News & Events

Based on Redbiotec’s rePAX® technology influenza VLP vaccine candidates were produced in a highly efficient way. This has been recently published in “Advances in Biotechnology and Biochemical Engineering” now available online.

Redbiotec AG announces today the appointment of Prof. Dr. Ralf Wagner, founder of Geneart, to Redbiotec’s team. We are both proud and pleased that Dr. Wagner joined our Company as scientific advisor. With his strong background in synthetic biology and vaccines he will strengthen our leading position in VLP vaccines. In addition to his scientific background, Ralf Wagner has a notable track record as entrepreneur. In 1999 he co-founded Geneart and brought it public to the German stock market in 2006, followed by a successful tradesale of Geneart to the US company Life Technologies (formerly Invitrogen) in 2010. Redbiotec is convinced that it will profit a lot from Ralf Wagner in the continuation of its leading business.

We are pleased to announce that Redbiotec has been labeled “High Potential SME” by the Swiss Economic Forum (SEF) through a certified process. This is a further proof for Redbiotec’s high value business.

Redbiotec AG has signed a new agreement with Roche Diagnostics GmbH, Germany, under which it will apply its proprietary technology platform rePAX® to produce VLPs. Roche intends to use the VLPs in an antibody discovery program in an undisclosed area.

Intercell and Redbiotec have successfully completed the proof of concept study, in which Redbiotec has applied its proprietary technology platform rePAX® in an undisclosed discovery area. Redbiotec looks forward to continue its collaboration with Intercell.